Researchers developed and evaluated a deep learning model for predicting coronavirus disease 2019 (COVID-19) acute respiratory distress syndrome (ARDS).

An AI-powered algorithm that sifts through data from multiple sources may help doctors quickly and accurately diagnose an ...

Convalescent plasma reduced mortality in COVID-19 patients with acute respiratory distress syndrome (ARDS) when provided within 5 days of invasive mechanical ventilation, the randomized open-label ...

The ARDS group included SARS-CoV-2 patients who required mechanical ventilation during their ICU stay, whereas the non-ARDS group included COVID-19 patients with mild to moderate symptoms.

Changes in pre-ECMO therapy between the first and second waves of COVID-19 or greater disease severity among patients on ECMO may explain the differences in outcomes, critical care specialists said.

Treatment with convalescent plasma reduced 28-day mortality among adults undergoing mechanical ventilation for COVID-19-induced acute respiratory distress syndrome, according to results published ...

A total of 25,677 (12.1%) cases of long COVID occurred among reinfected participants and 18,460 (8.7%) long-COVID cases ...

Key takeaways: Survival rates following transplantation did not differ between those with COVID-19 related ARDS or pulmonary fibrosis. Both groups also had similar rates of freedom from graft failure.

More Mortality After ECMO COVID-19 changed the survival equation for ARDS patients put on ECMO in an analysis of the National Inpatient Sample (NIS) database.

“The potential for ExoFlo to treat patients with ARDS represents an advancement in efforts to reduce morbidity and mortality caused by the serious inflammatory complications of COVID-19.” ...

A recent report by the American College of Obstetricians and Gynecologists strongly encourages pregnant women to stay up to ...